Invention Grant
- Patent Title: Modulation of splenocytes in cell therapy
-
Application No.: US15948617Application Date: 2018-04-09
-
Publication No.: US10758570B2Publication Date: 2020-09-01
- Inventor: Robert W. Mays
- Applicant: ABT Holding Company
- Applicant Address: US OH Cleveland
- Assignee: ABT Holding Company
- Current Assignee: ABT Holding Company
- Current Assignee Address: US OH Cleveland
- Agency: Tarolli, Sundheim, Covell & Tummino LLP
- Main IPC: A61K38/00
- IPC: A61K38/00 ; C12N5/00 ; A61K35/28 ; A61K35/545 ; C12N5/074 ; G01N33/50 ; G01N33/68

Abstract:
The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD4+ and CD8+ T-cells, increase IL-4 and IL-10, decrease IL-6 and IL-1β, and increase M2:M1 macrophage ratio at the site of injury. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to have these effects. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for achieving these effects.
Public/Granted literature
- US20180250342A1 MODULATION OF SPLENOCYTES IN CELL THERAPY Public/Granted day:2018-09-06
Information query
IPC分类: